Drug Profile
Monoclonal antibody CI-137
Latest Information Update: 29 May 1998
Price :
$50
*
At a glance
- Originator Zenyth Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 May 1998 Discontinued-Preclinical for Cancer in Australia (Unknown route)
- 01 Feb 1995 Preclinical development for Cancer in Australia (Unknown route)